SCHEMBL23988508

SCHEMBL23988508

CCOc1c(C)cnc(C[S+]([O-])c2nc3ccccc3[nH]2)c1C

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 5/20 0.47
WDR5 P61964 3/20 0.47
SARM1 Q6SZW1 1/20 0.46
NPC1 O15118 2/20 0.39
RAB9A P51151 2/20 0.39
ALDH1A1 P00352 3/20 0.37
HSD17B10 Q99714 3/20 0.37
KDM4E B2RXH2 3/20 0.37
LMNA P02545 2/20 0.37
SMN1; SMN2 Q16637 4/20 0.37
MAPT P10636 3/20 0.35
MEN1 O00255 2/20 0.35
HPGD P15428 2/20 0.35
HTT P42858 2/20 0.35
AR P10275 1/20 0.35
BRS3 P32247 2/20 0.35
DDAH1 O94760 2/20 0.35
CYP2C9 P11712 2/20 0.34
ABCB11 O95342 1/20 0.34
ATP1A1 P05023 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5348110 0.90 WDR5 (0.58) KMT2AWDR5SARM1NPC1RAB9A
SCHEMBL5348112 0.90 WDR5 (0.58) KMT2AWDR5SARM1NPC1RAB9A
SCHEMBL23988442 0.90 WDR5 (0.58) KMT2AWDR5SARM1NPC1RAB9A
SCHEMBL21945694 0.88 SARM1 (0.61) KMT2AWDR5SARM1NPC1RAB9A
SCHEMBL6440042 0.88 SARM1 (0.61) KMT2AWDR5SARM1NPC1RAB9A
SCHEMBL23988439 0.88 SARM1 (0.61) KMT2AWDR5SARM1NPC1RAB9A
SCHEMBL29323850 0.87 SARM1 (0.53) KMT2AWDR5SARM1NPC1RAB9A
SCHEMBL8119116 0.86 KMT2A (0.45) KMT2AWDR5SARM1NPC1RAB9A
SCHEMBL6877030 0.86 SARM1 (0.52) KMT2AWDR5SARM1NPC1RAB9A
SCHEMBL929030 0.86 KMT2A (0.43) KMT2AWDR5SARM1NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210338650-A1 CXCL10 Inhibitors AFECTA PHARMACEUTICALS, INC. (US) 2021-11-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210338650-A1 CXCL10 Inhibitors CXCL10, CCL5, CCL11 KMT2A 3380/4885WDR5 3395/4885SARM1 3076/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.